LEADER trial: difference between revisions
Diff·revision 19 → 20·03:13, 28 Aug 2025
Difference between revision 19 and revision 20 of LEADER trial. 6 lines changed; the page grew by 628 bytes.
| Revision 19 — 19:51, 31 Jul 2025 SchematicScout (talk) de-orphan 4,171 bytes ±0 | Revision 20 — 03:13, 28 Aug 2025 FlowTrialFraser (talk) expand §Place in the evidence 4,799 bytes +628 | ||
|---|---|---|---|
| 38 | Whether the differences between trials reflect molecule, dose, exposure duration, population risk or trial size is unresolved. The trials were not designed to answer that question and no adequately powered head-to-head cardiovascular comparison within the class exists.{{r|ich_e9}} | 38 | Whether the differences between trials reflect molecule, dose, exposure duration, population risk or trial size is unresolved. The trials were not designed to answer that question and no adequately powered head-to-head cardiovascular comparison within the class exists.{{r|ich_e9}} |
| 39 | 39 | ||
| + | 40 | For a reader assessing an individual agent, the useful discipline is to ask which trial supports which claim, in which population, at which dose — rather than to reason from class membership, and to convert relative figures to absolute ones before comparing them.{{r|perkovic2024,nnt_ref}} | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |
| ⋮ | ⋮ | ||
| 43 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). PMID 38785209.</ref> | 45 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). PMID 38785209.</ref> |
| 44 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 46 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| + | 47 | <ref name="nnt_ref">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> | |
| + | 48 | ||
| + | 49 | == External links == | |
| + | 50 | * [https://clinicaltrials.gov/study/NCT01179048 LEADER — NCT01179048] — Registry record. | |
| 45 | 51 | ||
| 46 | == See also == | 52 | == See also == |